Mycophenolate mofetil for autoimmune cytopenias in children: high rates of response in inborn errors of immunity

• Main Authors: Rubén Berrueco (Author), Elisa González-Forster (Author), Angela Deya-Martinez (Author), María Solsona (Author), Ana García-García (Author), Joan Calzada-Hernández (Author), Luo Yiyi (Author), Alexandru Vlagea (Author), Anna Ruiz-Llobet (Author), Laia Alsina (Author)
• Format: Book
• Published: Frontiers Media S.A., 2023-10-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Summary

Second-line treatments of autoimmune cytopenias (AC) are not well-defined in children. Mycophenolate mofetil (MMF) is an immunosuppressant agent that has been demonstrated to be safe and effective in this setting. A retrospective observational study was conducted in 18 children with prolonged AC who received MMF, in order to describe clinical and biological markers of response. The overall response rate of MMF at 20-30 mg/kg per day was 73.3%. All patients with Evans syndrome (n = 9) achieved complete response. Among the patients with monolineage AC (n = 9), those with an underlying inborn errors of immunity (IEI), tended to respond better to MMF. No biological markers related to treatment response were found. Rather, lymphocyte subpopulations proved useful for patient selection as a marker suggestive of IEI along with immunoglobulin-level determination.

Item Description

2296-2360
10.3389/fped.2023.1174671